(Q24808685)

16

Noriyuki Sato

0 references

Hiroko Asanuma

11

Hiroko Asanuma

0 references

Tomohide Tsukahara

6

Tomohide Tsukahara

0 references

Takuro Wada

2

Takuro Wada

0 references

Toshihide Yamashita

17

Toshihiko Yamashita

0 references

Hiroeki Sahara

8

Hiroeki Sahara

0 references

Yuriko Sato

4

Yuriko Sato

0 references

Satoshi Kawaguchi

1

Satoshi Kawaguchi

0 references

Hideyuki Ikeda

9

Hideyuki Ikeda

0 references

Kumiko Shimozawa

10

Kumiko Shimozawa

0 references

Hiroaki Hiraga

13

Hiroaki Hiraga

0 references

Kazunori Ida

3

Kazunori Ida

0 references

Satoshi Nagoya

5

Satoshi Nagoya

0 references

Sigeharu Kimura

7

Sigeharu Kimura

0 references

author name string

Takeshi Ishii

14

0 references

Shin-Ichiro Tatezaki

Journal of Translational Medicine

15

0 references

language of work or name

1 reference

12 January 2005

0 references

published in

0 references

volume

3

0 references

issue

1

0 references

page(s)

1

0 references

exact match

https://scigraph.springernature.com/pub.10.1186/1479-5876-3-1

0 references

cites work

Cancer immunotherapy: moving beyond current vaccines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=545052

Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=545052

Part I: Vaccines for solid tumours

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=545052

Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=545052

The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=545052

Crisscross CTL induction by SYT-SSX junction peptide and its HLA-A*2402 anchor substitute

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=545052

Synovial sarcoma: the importance of size and location for survival

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=545052

Current developments in cancer vaccines and cellular immunotherapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=545052

Synovial sarcoma of childhood and adolescence: a multicenter, multivariate analysis of outcome

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=545052

Chromosomal translocation products engender new intracellular therapeutic technologies

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=545052

Improved generation of HLA class I/peptide tetramers

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=545052

Emerging strategies in tumor vaccines.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=545052

Detection and induction of CTLs specific for SYT-SSX-derived peptides in HLA-A24(+) patients with synovial sarcoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=545052

Chromosomal translocations and sarcomas

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=545052

Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=545052

Soft tissue sarcoma as a model disease to examine cancer immunotherapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=545052

Immunotherapy with autologous dendritic cells and tumor-specific synthetic peptides for synovial sarcoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=545052

Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses

28 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/15647119

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1479-5876-3-1

1 reference

Dimensions Publication ID

3529261

1002229798

0 references

3529261

1 reference

1 reference

1 reference